Bringing Emerging Therapies Under the CLAA Framework

Why in News?

Recently, The Central Government has amended the Drugs Rules, 1945, bringing stem cell-derived products, gene therapeutic products, and xenografts under the Centrally Licensed Approving Authority (CLAA) framework. The amendment aims to strengthen regulatory oversight over advanced biological therapies, ensure patient safety, and facilitate the responsible adoption of emerging medical technologies in India.

What is the Centrally Licensed Approving Authority (CLAA)?

The Centrally Licensed Approving Authority (CLAA) is a regulatory mechanism under the Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945. It provides joint regulatory oversight by the Central Drugs Standard Control Organisation (CDSCO) and State Licensing Authorities for drugs and biological products that require stringent quality and safety standards. Earlier, products such as vaccines, recombinant DNA (r-DNA) medicines, and large-volume parenterals were covered under CLAA. The latest amendment expands this framework to include advanced therapies.

Key Emerging Therapies Covered:

The amendment covers three categories of advanced biological products:

• • • Stem Cell-Derived Products: Therapies that use stem cells to repair or replace damaged tissues, with applications in regenerative medicine and blood disorders.
    • Gene Therapeutic Products: Treatments that modify or replace defective genes to treat inherited disorders, cancers, and rare genetic diseases.
    • Xenografts: Animal tissue-derived products, such as pig heart valves and skin grafts, used in cardiology and reconstructive surgeries.

Need for Enhanced Regulation:

Cell and gene therapies involve living cells, genetic manipulation, and highly specialized manufacturing processes. These technologies carry risks such as immune reactions, unintended genetic changes, and long-term safety concerns. Centralized regulatory oversight under CLAA ensures uniform scientific evaluation, quality assurance, and patient safety while promoting responsible innovation. It also supports the development of indigenous therapies such as Chimeric Antigen Receptor T-cell (CAR-T) therapy, which offers promising treatment for blood cancers.

Regulatory Framework in India:

The Drugs and Cosmetics Act, 1940 is the principal legislation regulating the import, manufacture, distribution, and sale of drugs, cosmetics, and medical devices in India. The Drugs Rules, 1945 prescribe licensing procedures, manufacturing standards, and drug schedules. The CDSCO serves as the national regulatory authority, while the Drugs Technical Advisory Board (DTAB) and the Drugs Consultative Committee (DCC) provide technical guidance and coordination. Stem cell research is governed by the National Guidelines for Stem Cell Research, jointly issued by the Indian Council of Medical Research (ICMR) and the Department of Biotechnology (DBT).

Significance:

The amendment strengthens India's biotechnology ecosystem by ensuring robust regulation of advanced therapies while encouraging innovation. It enhances public confidence, aligns India's regulatory framework with global standards, and supports the development of affordable indigenous treatments.

Conclusion:

strengthening regulatory capacity, promoting ethical clinical research, and improving access to advanced therapies will be essential to harness the full potential of regenerative medicine and gene therapy while safeguarding patient safety.